Akebia Therapeutics (NASDAQ:AKBA) Lowered to “Sell” Rating by StockNews.com
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Thursday. Separately, HC Wainwright reissued a “buy” rating and set a $7.50 price objective on shares of Akebia Therapeutics in a report on Thursday, January 23rd. Check Out […]
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Thursday. Separately, HC Wainwright reissued a “buy” rating and set a $7.50 price objective on shares of Akebia Therapeutics in a report on Thursday, January 23rd. Check Out […]
